Abstract
Radionuclide molecular imaging of human epidermal growth factor receptor 2 (HER2) in breast and gastroesophageal cancer might be used to stratify patients for HER2-targeted therapy as well as monitor treatment response and disease progression. Designed ankyrin repeat proteins (DARPins) are small engineered scaffold proteins with favorable properties for molecular imaging. Herein we compared two methods for labeling the anti-HER2 DARPin (HE)3-G3, direct and indirect radioiodination. We hypothesized that the use of N-succinimidyl-para-iodobenzoate (SPIB) for radioiodination would facilitate the clearance of radiometabolites and improve the contrast of imaging. Both radiolabeled (HE)3-G3 variants preserved their binding specificity and high affinity to HER2-expressing cells. The specificity of tumor targeting in vivo was also demonstrated. A biodistribution comparison of [125I]I-(HE)3-G3 and [125I]I-PIB-(HE)3-G3, in mice bearing HER2 expressing SKOV3 xenografts, showed rapid clearance of [125I]I-PIB-(HE)3-G3 from normal organs and tissues and low accumulation of activity in organs with NaI-symporter expression. Both radiolabeled (HE)3-G3 variants had equal tumor uptake. Consequently, the indirect label provided higher tumor-to-blood and tumor-to-organ ratios compared with the direct label. Comparative Single Photon Emission Computed Tomography (SPECT)/CT imaging of HER2 expression in SKOV3 xenografts, using both radiolabeled DARPins, demonstrated the superior imaging contrast of the indirect label. Indirect radioiodination of (HE)3-G3 using SPIB could be further applied for SPECT and PET imaging with iodine-123 and iodine-124.
Highlights
The mechanism of action of targeted anti-cancer biopharmaceuticals includes the molecular recognition of gene products that are overexpressed or mutated in malignant tumors
New types of molecular imaging probes based on engineered scaffold proteins (ESPs) have emerged [2]
human epidermal growth factor receptor 2 (HER2)-expressing SKOV3, BT474 and DU145 cells and HER2-negative Ramos cells from the American Type Culture Collection (ATCC) were cultured in RPMI medium supplemented with 10% fetal bovine serum (Merck, Darmstadt, Germany), 2 mM L-glutamine, 100 IU/mL penicillin and 100 μg/mL streptomycin in a humidified incubator with 5% CO2 at 37 ◦C, unless stated otherwise
Summary
The mechanism of action of targeted anti-cancer biopharmaceuticals includes the molecular recognition of gene products that are overexpressed or mutated in malignant tumors. These targeted biopharmaceuticals are successfully used for treatment of disseminated cancer. Radionuclide molecular imaging of a target’s expression in tumors might be a facile way to stratify patients for treatment using biopharmaceuticals [1]. This approach is not prone to sampling errors and is non-invasive, which permits determining the expression level repeatedly in order to monitor its changes during disease progression [1]. This results in a low background activity in the body and, a high contrast of imaging [2]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have